SUPERNUS PHARMACEUTICALS, INC. Revenues
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Revenues of $94.98 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-15.
Discontinued › Income Statement › Revenue
us-gaap:Revenues · last filed 2020-05-15
- SUPERNUS PHARMACEUTICALS, INC. revenues for the quarter ending 2020-03-31 was $94.98M, a 11.12% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. revenues for the quarter ending 2019-12-31 was $100.45M, a 13.36% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. revenues for the quarter ending 2019-09-30 was $102.14M, a 0.83% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. revenues for the quarter ending 2019-06-30 was $104.69M, a 5.18% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. revenues for fiscal 2019 was $392.75M, a 3.95% decline from fiscal 2018.
- SUPERNUS PHARMACEUTICALS, INC. revenues for fiscal 2018 was $408.90M, a 35.29% increase from fiscal 2017.
- SUPERNUS PHARMACEUTICALS, INC. revenues for fiscal 2017 was $302.24M, a 40.57% increase from fiscal 2016.
- SUPERNUS PHARMACEUTICALS, INC. revenues for fiscal 2016 was $215.00M, a 45.80% increase from fiscal 2015.
| Period end | Revenues 3 month | Revenues 3 month as first filed | Revenues 6 month | Revenues 6 month as first filed | Revenues 9 month | Revenues 9 month as first filed | Revenues 12 month | Revenues 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2020-03-31 | $94.98M 10-Q · filed 2020-05-15 | $195.42M derived: sum of 2 quarters · filed 2020-05-15 | $297.56M derived: sum of 3 quarters · filed 2020-05-15 | $402.26M derived: sum of 4 quarters · filed 2020-05-15 | ||||
| 2019-12-31 | $100.45M 10-K · filed 2020-02-28 | $202.59M derived: sum of 2 quarters · filed 2020-02-28 | $307.28M derived: sum of 3 quarters · filed 2020-02-28 | $392.75M 10-K · filed 2020-02-28 | ||||
| 2019-09-30 | $102.14M 10-K · filed 2020-02-28 | $206.84M derived: sum of 2 quarters · filed 2020-02-28 | $292.31M 10-Q · filed 2019-11-08 | $408.24M derived: sum of 4 quarters · filed 2020-05-15 | ||||
| 2019-06-30 | $104.69M 10-K · filed 2020-02-28 | $190.17M 10-Q · filed 2019-08-09 | $306.10M derived: sum of 3 quarters · filed 2020-05-15 | $409.10M derived: sum of 4 quarters · filed 2020-05-15 | ||||
| 2019-03-31 | $85.47M 10-Q · filed 2020-05-15 | $201.41M derived: sum of 2 quarters · filed 2020-05-15 | $304.40M derived: sum of 3 quarters · filed 2020-05-15 | $403.94M derived: sum of 4 quarters · filed 2020-05-15 | ||||
| 2018-12-31 | $115.93M 10-K · filed 2020-02-28 | $218.93M derived: sum of 2 quarters · filed 2020-02-28 | $318.47M derived: sum of 3 quarters · filed 2020-02-28 | $408.90M 10-K · filed 2020-02-28 | ||||
| 2018-09-30 | $103.00M 10-K · filed 2020-02-28 | $202.53M derived: sum of 2 quarters · filed 2020-02-28 | $292.96M 10-Q · filed 2019-11-08 | $381.40M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-06-30 | $99.54M 10-K · filed 2020-02-28 | $189.97M 10-Q · filed 2019-08-09 | $278.40M derived: sum of 3 quarters · filed 2020-02-28 | $358.80M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-03-31 | $90.43M 10-K · filed 2020-02-28 | $178.86M derived: sum of 2 quarters · filed 2020-02-28 | $259.26M derived: sum of 3 quarters · filed 2020-02-28 | $335.09M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2017-12-31 | $88.44M 10-K · filed 2019-03-01 | $168.83M derived: sum of 2 quarters · filed 2019-03-01 | $244.66M derived: sum of 3 quarters · filed 2019-03-01 | $302.24M 10-K · filed 2020-02-28 | ||||
| 2017-09-30 | $80.40M 10-K · filed 2019-03-01 | $156.23M derived: sum of 2 quarters · filed 2019-03-01 | $213.80M 10-Q · filed 2018-11-09 | $276.18M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-06-30 | $75.83M 10-K · filed 2019-03-01 | $133.41M 10-Q · filed 2018-08-09 | $195.78M derived: sum of 3 quarters · filed 2019-03-01 | $252.59M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-03-31 | $57.58M 10-K · filed 2019-03-01 | $119.95M derived: sum of 2 quarters · filed 2019-03-01 | $176.76M derived: sum of 3 quarters · filed 2019-03-01 | $228.39M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2016-12-31 | $62.37M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $119.18M derived: sum of 2 quarters · filed 2019-03-01 | $170.81M derived: sum of 3 quarters · filed 2019-03-01 | $215.00M 10-K · filed 2019-03-01 | ||||
| 2016-09-30 | $56.81M 10-Q · filed 2017-11-09 | $108.44M derived: sum of 2 quarters · filed 2017-11-09 | $152.63M 10-Q · filed 2017-11-09 | $196.32M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-06-30 | $51.63M 10-Q · filed 2017-08-03 | $50.42M 10-Q · filed 2016-08-05 | $95.82M 10-Q · filed 2017-08-03 | $93.50M 10-Q · filed 2016-08-05 | $139.51M derived: sum of 3 quarters · filed 2018-03-01 | $178.87M derived: sum of 4 quarters · filed 2018-03-01 | ||
| 2016-03-31 | $44.19M 10-Q · filed 2017-05-09 | $43.08M 10-Q · filed 2016-05-10 | $87.88M derived: sum of 2 quarters · filed 2018-03-01 | $127.24M derived: sum of 3 quarters · filed 2018-03-01 | $162.92M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2015-12-31 | $43.69M derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-01 | $83.05M derived: sum of 2 quarters · filed 2018-03-01 | $118.73M derived: sum of 3 quarters · filed 2018-03-01 | $147.47M 10-K · filed 2018-03-01 | $144.43M 10-K · filed 2016-03-09 | |||
| 2015-09-30 | $39.36M 10-Q/A · filed 2017-01-20 | $38.59M 10-Q · filed 2015-11-09 | $75.04M derived: sum of 2 quarters · filed 2017-01-23 | $103.78M 10-Q/A · filed 2017-01-20 | $101.77M 10-Q · filed 2015-11-09 | $135.01M derived: sum of 4 quarters · filed 2017-03-16 | ||
| 2015-06-30 | $35.68M 10-Q/A · filed 2017-01-23 | $35.05M 10-Q · filed 2015-08-07 | $64.42M 10-Q/A · filed 2017-01-23 | $63.19M 10-Q · filed 2015-08-07 | $95.65M derived: sum of 3 quarters · filed 2017-03-16 | $118.34M derived: sum of 4 quarters · filed 2017-03-16 | ||
| 2015-03-31 | $28.74M 10-Q/A · filed 2017-01-20 | $28.13M 10-Q · filed 2015-05-06 | $59.97M derived: sum of 2 quarters · filed 2017-03-16 | $82.66M derived: sum of 3 quarters · filed 2017-03-16 | $112.33M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | $31.23M derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-16 | $53.92M derived: sum of 2 quarters · filed 2017-03-16 | $83.60M derived: sum of 3 quarters · filed 2017-03-16 | $92.68M 10-K · filed 2017-03-16 | $122.05M 10-K · filed 2015-03-12 | |||
| 2014-09-30 | $22.69M 10-Q/A · filed 2017-01-20 | $52.49M 10-Q · filed 2014-11-12 | $52.36M derived: sum of 2 quarters · filed 2017-01-20 | $61.44M 10-Q/A · filed 2017-01-20 | $91.24M 10-Q · filed 2014-11-12 | $71.78M derived: sum of 4 quarters · filed 2017-01-20 | ||
| 2014-06-30 | $29.68M 10-Q · filed 2015-08-07 | $38.76M 10-Q · filed 2015-08-07 | $49.09M derived: sum of 3 quarters · filed 2017-01-20 | $50.35M derived: sum of 4 quarters · filed 2017-01-20 | ||||
| 2014-03-31 | $9.08M 10-Q · filed 2015-05-06 | $19.42M derived: sum of 2 quarters · filed 2017-01-20 | $20.67M derived: sum of 3 quarters · filed 2017-01-20 | $20.95M derived: sum of 4 quarters · filed 2017-01-20 | ||||
| 2013-12-31 | $10.34M derived: 10-K/A 12 month − 10-Q 9 month · filed 2017-01-20 | $11.59M derived: sum of 2 quarters · filed 2017-01-20 | $11.87M derived: sum of 3 quarters · filed 2017-01-20 | $12.02M 10-K/A · filed 2017-01-20 | ||||
| 2013-09-30 | $1.26M 10-Q · filed 2014-11-12 | $1.54M derived: sum of 2 quarters · filed 2014-11-12 | $1.68M 10-Q · filed 2014-11-12 | $2.77M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-06-30 | $281.00K 10-Q · filed 2014-08-12 | $428.00K 10-Q · filed 2014-08-12 | $1.52M derived: sum of 3 quarters · filed 2015-03-12 | $1.61M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-03-31 | $147.00K 10-Q · filed 2014-05-13 | $1.24M derived: sum of 2 quarters · filed 2015-03-12 | $1.33M derived: sum of 3 quarters · filed 2015-03-12 | $1.42M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2012-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $1.18M derived: sum of 2 quarters · filed 2015-03-12 | $1.27M derived: sum of 3 quarters · filed 2015-03-12 | $1.48M 10-K · filed 2015-03-12 | ||||
| 2012-09-30 | $91.00K 10-Q · filed 2013-11-13 | $182.00K derived: sum of 2 quarters · filed 2013-11-13 | $391.00K 10-Q · filed 2013-11-13 | |||||
| 2012-06-30 | $91.00K 10-Q · filed 2013-08-14 | $299.00K 10-Q · filed 2013-08-14 | ||||||
| 2011-12-31 | $803.00K 10-K · filed 2014-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |